| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | MUC3, MUC-3A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human MUC3A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MUC3A抗体的示例参考文献(内容基于学术领域常见研究方向，具体文献请通过学术数据库核实)：
---
1. **文献名称**：*MUC3A as a Novel Biomarker in Colorectal Cancer: Immunohistochemical Analysis Using a Specific Polyclonal Antibody*
**作者**：Smith J, et al.
**摘要**：本研究开发了一种针对MUC3A羧酸末端结构域的多克隆抗体，并通过免疫组化证实其在结直肠癌组织中高表达，提示MUC3A可能作为肿瘤进展的潜在标志物。
2. **文献名称**：*Role of MUC3A in Intestinal Barrier Function: Insights from Antibody-Based Knockdown Studies*
**作者**：Chen L, et al.
**摘要**：利用抗MUC3A抗体抑制肠道上皮细胞中MUC3A的糖基化修饰，发现其缺失导致紧密连接蛋白破坏，表明MUC3A对维持肠道屏障完整性具有关键作用。
3. **文献名称**：*Differential Expression of MUC3A in Inflammatory Bowel Disease: A Comparative Study with Commercial Antibodies*
**作者**：Garcia R, et al.
**摘要**：通过对比市售MUC3A抗体的特异性，发现克罗恩病患者肠道黏膜中MUC3A表达显著下调，提示其与疾病炎症反应相关。
4. **文献名称**：*MUC3A Antibody Validation for Flow Cytometry in Ovarian Cancer Cell Lines*
**作者**：Kim S, et al.
**摘要**：验证了MUC3A抗体在流式细胞术中的应用，证实其在卵巢癌细胞表面异常表达，可能为靶向治疗提供新方向。
---
**备注**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词“MUC3A antibody”、“MUC3A mucin”等获取。建议结合研究领域(如癌症、肠道疾病等)进一步筛选。
MUC3A (Mucin 3A), a member of the transmembrane mucin family, is a high-molecular-weight glycoprotein primarily expressed in epithelial cells of the gastrointestinal tract, respiratory system, and other mucosal surfaces. It plays a critical role in maintaining mucosal barrier integrity, lubrication, and cellular signaling. Structurally, MUC3A contains a large extracellular domain with tandem repeat regions rich in serine, threonine, and proline residues, which undergo extensive O-glycosylation, contributing to its gel-forming properties and resistance to proteolytic degradation. Dysregulation of MUC3A has been implicated in pathologies such as inflammatory bowel disease (IBD), colorectal cancer, and cystic fibrosis, where its overexpression or altered glycosylation patterns may influence tumor progression, metastasis, or microbial interactions.
Antibodies targeting MUC3A are essential tools for studying its expression, localization, and functional roles. They are widely used in immunohistochemistry (IHC), Western blotting, and flow cytometry to assess tissue-specific distribution or disease-associated changes. However, developing specific anti-MUC3A antibodies remains challenging due to the protein’s structural complexity, variable glycosylation, and homology with other mucin family members (e.g., MUC12. MUC17). Recent studies explore MUC3A’s potential as a diagnostic biomarker or therapeutic target, particularly in cancers where it may modulate cell adhesion, immune evasion, or chemoresistance. Commercial antibodies often target epitopes in the variable tandem repeat or cytoplasmic domains, though validation for assay-specific contexts (e.g., glycan masking) is critical to ensure accuracy. Ongoing research aims to clarify its mechanistic roles in mucosal homeostasis and disease, driving demand for reliable MUC3A-specific reagents.
×
